- Home
- GDTC vs AKTX Comparison
GDTC vs AKTX Comparison
Compare GDTC & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- AKTX
- Stock Information
- Founded
- GDTC 2018
- AKTX N/A
- Country
- GDTC Singapore
- AKTX United States
- Employees
- GDTC N/A
- AKTX N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- AKTX Health Care
- Exchange
- GDTC Nasdaq
- AKTX Nasdaq
- Market Cap
- GDTC 28.0M
- AKTX 29.1M
- IPO Year
- GDTC 2023
- AKTX N/A
- Fundamental
- Price
- GDTC $2.40
- AKTX $1.45
- Analyst Decision
- GDTC Buy
- AKTX
- Analyst Count
- GDTC 1
- AKTX 0
- Target Price
- GDTC $5.00
- AKTX N/A
- AVG Volume (30 Days)
- GDTC 32.5K
- AKTX 28.2K
- Earning Date
- GDTC 01-01-0001
- AKTX 04-16-2025
- Dividend Yield
- GDTC N/A
- AKTX N/A
- EPS Growth
- GDTC N/A
- AKTX N/A
- EPS
- GDTC N/A
- AKTX N/A
- Revenue
- GDTC $330,254.00
- AKTX N/A
- Revenue This Year
- GDTC $14.71
- AKTX N/A
- Revenue Next Year
- GDTC N/A
- AKTX N/A
- P/E Ratio
- GDTC N/A
- AKTX N/A
- Revenue Growth
- GDTC N/A
- AKTX N/A
- 52 Week Low
- GDTC $1.20
- AKTX $0.85
- 52 Week High
- GDTC $4.05
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- GDTC 48.41
- AKTX 64.05
- Support Level
- GDTC $2.20
- AKTX $1.03
- Resistance Level
- GDTC $2.46
- AKTX $1.58
- Average True Range (ATR)
- GDTC 0.21
- AKTX 0.16
- MACD
- GDTC 0.01
- AKTX 0.02
- Stochastic Oscillator
- GDTC 34.67
- AKTX 77.72
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).